Advances in the treatment of neurodegenerative disorders employing nanotechnology

Due to limitations posed by the restrictive blood–brain barrier, conventional drug delivery systems do not provide adequate cyto‐architecture restoration and connection patterns that are essential for functional recovery in neurodegenerative disorders (NDs). Nanotechnology employs engineered materials or devices that interact with biological systems at a molecular level and could revolutionize the treatment of NDs by stimulating, responding to, and interacting with target sites to induce physiological responses while minimizing side effects. This review provides a concise discussion of the current applications of nano‐enabled drug‐delivery systems for the treatment of NDs, in particular Alzheimer's and Parkinson's diseases, and explores the future applications of nanotechnology in clinical neuroscience to develop innovative therapeutic modalities for the treatment of NDs.

[1]  M. Horne,et al.  Neural tissue engineering of the CNS using hydrogels. , 2008, Journal of biomedical materials research. Part B, Applied biomaterials.

[2]  M. Apuzzo,et al.  Toward the emergence of nanoneurosurgery: part III--nanomedicine: targeted nanotherapy, nanosurgery, and progress toward the realization of nanoneurosurgery. , 2008, Neurosurgery.

[3]  K. Subramani,et al.  Self-Assembly of Proteins and Peptides and their Applications in Bionanotechnology , 2008 .

[4]  J. Chaput,et al.  Synthesis of two mirror image 4-helix junctions derived from glycerol nucleic acid. , 2008, Journal of the American Chemical Society.

[5]  Hao Yan,et al.  Self-Assembled Water-Soluble Nucleic Acid Probe Tiles for Label-Free RNA Hybridization Assays , 2008, Science.

[6]  C. Foged,et al.  Cell-penetrating peptides for drug delivery across membrane barriers , 2008, Expert opinion on drug delivery.

[7]  I. Roy,et al.  ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology , 2007, Journal of Neuroscience Methods.

[8]  John C. Chaput,et al.  Experimental Evidence That GNA and TNA Were Not Sequential Polymers in the Prebiotic Evolution of RNA , 2007, Journal of Molecular Evolution.

[9]  Y. Nagasaki,et al.  Endosomal release and intracellular delivery of anticancer drugs using pH-sensitive PEGylated nanogels , 2007 .

[10]  H. Gendelman,et al.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. , 2007, Progress in polymer science.

[11]  V. Pillay,et al.  Patenting of nanopharmaceuticals in drug delivery: no small issue. , 2007, Recent patents on drug delivery & formulation.

[12]  S. Mandel,et al.  Nanoparticles: a step forward for iron chelation in the brain , 2007 .

[13]  Neha Singh,et al.  Advances in the treatment of Parkinson's disease , 2007, Progress in Neurobiology.

[14]  T. Witzig.  Radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2006, Best practice & research. Clinical haematology.

[15]  John W. Park,et al.  Real-time Imaging and Quantification of Brain Delivery of Liposomes , 2006, Pharmaceutical Research.

[16]  P. Flachenecker.  Epidemiology of neuroimmunological diseases , 2006, Journal of Neurology.

[17]  A. Kabanov,et al.  Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[18]  P. Borm,et al.  Nanoparticles in drug delivery and environmental exposure: same size, same risks? , 2006, Nanomedicine.

[19]  R. Puri,et al.  Convection-enhanced Delivery of Interleukin-13 Receptor-directed Cytotoxin for Malignant Glioma Therapy* , 2006, Technology in cancer research & treatment.

[20]  M. Apuzzo,et al.  Toward the Emergence of Nanoneurosurgery: Part III—Nanomedicine: Targeted Nanotherapy, Nanosurgery, and Progress Toward the Realization of Nanoneurosurgery , 2006, Neurosurgery.

[21]  P. Brundin,et al.  Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. , 2006, International journal of pharmaceutics.

[22]  T. Aziz,et al.  Surgical insights into Parkinson's disease. , 2006, Journal of the Royal Society of Medicine.

[23]  T. Witzig,et al.  Radioimmunotherapy for B-cell non-Hodgkin lymphoma. , 2006, Clinical advances in hematology & oncology : H&O.

[24]  Aibing Yu,et al.  Inorganic nanoparticles as carriers for efficient cellular delivery , 2006 .

[25]  Andrew D. Miller,et al.  Synthetic, Self‐Assembly ABCD Nanoparticles; a Structural Paradigm for Viable Synthetic Non‐Viral Vectors , 2006 .

[26]  L. Shlyakhtenko,et al.  Template-assisted synthesis of nanogels from Pluronic-modified poly(acrylic acid) , 2006, Journal of drug targeting.

[27]  William Shain,et al.  An endothelial and astrocyte co-culture model of the blood-brain barrier utilizing an ultra-thin, nanofabricated silicon nitride membrane. , 2005, Lab on a chip.

[28]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[29]  A. R. Kulkarni,et al.  Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[30]  C. Müller-Goymann,et al.  Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). , 2005, International journal of pharmaceutics.

[31]  Andrew D. Miller,et al.  Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. , 2005, Chemical Society Reviews.

[32]  A. Kabanov,et al.  Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[33]  Younan Xia,et al.  Polymer hollow particles with controllable holes in their surfaces , 2005, Nature materials.

[34]  M. Prato,et al.  Carbon nanotube substrates boost neuronal electrical signaling. , 2005, Nano letters.

[35]  N. Seeman.  From genes to machines: DNA nanomechanical devices. , 2005, Trends in biochemical sciences.

[36]  Russell J Mumper,et al.  Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[37]  J. McArthur.  HIV dementia: an evolving disease , 2004, Journal of Neuroimmunology.

[38]  C. Masters,et al.  Metal-protein attenuating compounds and Alzheimer’s disease , 2004, Expert opinion on investigational drugs.

[39]  G. Storm,et al.  Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[40]  D. Begley.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[41]  K. Marder.  Memantine approved to treat moderate to severe Alzheimer’s disease , 2004, Current Neurology and Neuroscience Reports.

[42]  J. Kreuter.  Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. , 2004, Journal of nanoscience and nanotechnology.

[43]  K. Geiger,et al.  Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles , 2004, International journal of cancer.

[44]  R. Müller,et al.  Drug delivery to the brain--realization by novel drug carriers. , 2004, Journal of nanoscience and nanotechnology.

[45]  Sung Keun Kang,et al.  Evidence of a Pluripotent Human Embryonic Stem Cell Line Derived from a Cloned Blastocyst , 2004, Science.

[46]  Riyi Shi,et al.  Decreased functions of astrocytes on carbon nanofiber materials. , 2004, Biomaterials.

[47]  Raphael Pfeffer,et al.  Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. , 2004, Journal of neurosurgery.

[48]  Krista L. Niece,et al.  Selective Differentiation of Neural Progenitor Cells by High-Epitope Density Nanofibers , 2004, Science.

[49]  S. V. Lebedev,et al.  PEGylated Immunoliposomes Directed Against Brain Astrocytes , 2004, Drug delivery.

[50]  E. Neuwelt.  Mechanisms of Disease: The Blood-Brain Barrier , 2004, Neurosurgery.

[51]  A. Curtis,et al.  Receptor-mediated targeting of magnetic nanoparticles using insulin as a surface ligand to prevent endocytosis , 2003, IEEE Transactions on NanoBioscience.

[52]  Jianmin Gao,et al.  A Four-Base Paired Genetic Helix with Expanded Size , 2003, Science.

[53]  M. Beal,et al.  Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice , 2003, Nature Biotechnology.

[54]  Yan Liu,et al.  DNA-Templated Self-Assembly of Protein Arrays and Highly Conductive Nanowires , 2003, Science.

[55]  R. Gold,et al.  Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. , 2003, Brain : a journal of neurology.

[56]  David A. Tirrell,et al.  Engineering of the Extracellular Matrix: Working toward Neural Stem Cell Programming and Neurorestoration— Concept and Progress Report , 2003 .

[57]  George Perry,et al.  Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. , 2003, Biochemistry.

[58]  D. Begley,et al.  Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.

[59]  E. Parati,et al.  Neural stem cells. Biological features and therapeutic potential in Parkinson's disease. , 2003, Journal of neurosurgical sciences.

[60]  T. Harkany,et al.  Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease , 2003, Neuroscience Letters.

[61]  Anders Björklund,et al.  Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[62]  O. Lindvall,et al.  Role of cell therapy in Parkinson disease. , 2002, Neurosurgical focus.

[63]  D. Trombetta,et al.  Design and Characterization of Liposomes Containing Long-Chain N-AcylPEs for Brain Delivery: Penetration of Liposomes Incorporating GM1 into the Rat Brain , 2002, Pharmaceutical Research.

[64]  M. Simionescu,et al.  Designing of ‘intelligent’ liposomes for efficient delivery of drugs , 2002, Journal of cellular and molecular medicine.

[65]  G. Miller.  Breaking Down Barriers , 2002, Science.

[66]  R. McKay,et al.  Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease , 2002, Nature.

[67]  Patrick Couvreur,et al.  Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat , 2002, The European journal of neuroscience.

[68]  K. Kataoka,et al.  Polyion complex micelles as vectors in gene therapy – pharmacokinetics and in vivo gene transfer , 2002, Gene Therapy.

[69]  Vladimir P Torchilin,et al.  PEG-based micelles as carriers of contrast agents for different imaging modalities. , 2002, Advanced drug delivery reviews.

[70]  Peter Ramge,et al.  Apolipoprotein-mediated Transport of Nanoparticle-bound Drugs Across the Blood-Brain Barrier , 2002, Journal of drug targeting.

[71]  W. Pardridge,et al.  Brain-specific expression of an exogenous gene after i.v. administration , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Couvreur,et al.  Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery , 2001, Pharmaceutical Research.

[73]  C. Olanow,et al.  Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.

[74]  N. Behan,et al.  Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. , 2001, Biomaterials.

[75]  C. Masters,et al.  Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.

[76]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[77]  J. Kreuter,et al.  Nanoparticulate systems for brain delivery of drugs. , 2001, Advanced drug delivery reviews.

[78]  J. Coyle,et al.  Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease , 2001, Biological Psychiatry.

[79]  C. Gorman.  Heart disease. Rethinking treatments for the heart. , 2001, Time.

[80]  R. Löbenberg,et al.  Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier in vivo and in vitro , 2001, Journal of drug targeting.

[81]  C. Niemeyer,et al.  Self-assembled nanostructures based on DNA: towards the development of nanobiotechnology. , 2000, Current opinion in chemical biology.

[82]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[83]  S. Davis,et al.  Biomedical applications of nanotechnology--implications for drug targeting and gene therapy. , 1997, Trends in biotechnology.

[84]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[85]  J. Simpkins,et al.  The brain-targeted delivery of dopamine using a redox-based chemical delivery system , 1994 .

[86]  P F Morrison,et al.  Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[87]  M. Fiandaca,et al.  Image-guided convection-enhanced delivery platform in the treatment of neurological diseases , 2011, Neurotherapeutics.

[88]  K. Jain.  The role of nanobiotechnology in drug discovery. , 2009, Advances in experimental medicine and biology.

[89]  A. Gaur,et al.  Significance of nanotechnology in medical sciences , 2008 .

[90]  R. Andrews,et al.  Trimodal nanoelectrode array for precise deep brain stimulation: prospects of a new technology based on carbon nanofiber arrays. , 2007, Acta neurochirurgica. Supplement.

[91]  Jun Li,et al.  Vertically aligned carbon nanofiber arrays: an advance toward electrical-neural interfaces. , 2006, Small.

[92]  Antonio Turiel,et al.  Nanoparticle-mediated local and remote manipulation of protein aggregation. , 2006, Nano letters.

[93]  Deborah Gustafson,et al.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.

[94]  M. Apuzzo,et al.  Engineering of the extracellular matrix: working toward neural stem cell programming and neurorestoration--concept and progress report. , 2003, Neurosurgery.

[95]  G. Miller.  Drug targeting. Breaking down barriers. , 2002, Science.

[96]  A. Kabanov,et al.  Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents , 2000, Gene Therapy.

[97]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[98]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.